Latest news and press releases about Kazia Therapeutics Ltd ADR (KZIA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous...
Price
| Price | $10.20 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | AU |
Valuation Ratios
| Price / Book | 0.95 |
| EV / EBITDA | 2.30 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -116.86% |
| Return on Invested Capital | -36.21% |
| Return on Assets | -31.35% |
| Gross Margin | 100.00% |
| Operating Margin | -92086.45% |
| Net Margin | -113004.58% |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KZIA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks